Hirotaka Nagasaka

Dr. Hirotaka Nagasaka

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2024 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
HNHirotaka Nagasaka
Hirotaka Nagasaka
TKTakeshi Kishida
Takeshi Kishida
TKTaku Kouro
Taku Kouro
YIYuka Igarashi
Yuka Igarashi
STShinichi Takebe
Shinichi Takebe
Tetsuro SasadaTetsuro Sasada
Tetsuro Sasada
Background: Few studies have reported reliable prognostic factors for immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC). Therefore, we investigated prognostic factors in patients treated with ICIs for unresectable or metastatic RCC. Methods: We included 43 patients who received ICI treatment for RCC between January 2018 and October 2021. Blood samples were drawn before treatment, and 73 soluble factors in the plasma were analyzed using a bead-based multiplex assay. We examined factors associated with progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAE) using the Chi-squared test, Kaplan–Meier method, and the COX proportional hazards model. Results: Patients exhibited a median PFS and OS of 212 and 783 days, respectively. Significant differences in both PFS and OS were observed for MMP1 (PFS, p < 0.001; OS, p = 0.003), IL-1β (PFS, p = 0.021; OS, p = 0.008), sTNFR-1 (PFS, p = 0.017; OS, p = 0.005), and IL-6 (PFS, p = 0.004; OS, p < 0.001). Multivariate analysis revealed significant differences in PFS for MMP1 (hazard ratio [HR] 5.305, 95% confidence interval [CI], 1.648–17.082; p = 0.005) and OS for IL-6 (HR 23.876, 95% CI, 3.426–166.386; p = 0.001). Moreover, 26 patients experienced irAE, leading to ICI discontinuation or withdrawal. MMP1 was significantly associated with irAE (p = 0.039). Conclusion: MMP1 may be associated with severe irAE, and MMP1, IL-1β, sTNFR-1, and IL-6 could serve as prognostic factors in unresectable or metastatic RCC treated with ICIs. MMP1 and IL-6 were independent predictors of PFS and OS, respectively. Thus, inhibiting these soluble factors may be promising for enhancing antitumor responses in patients with RCC treated with ICIs.

27 June 2024 in In Vivo
Verified
Journal Article
Open access
PDF file
HNHirotaka Nagasaka
Hirotaka Nagasaka
SYShotaro Yamamoto
Shotaro Yamamoto
ASAtsuto Suzuki
Atsuto Suzuki
KUKimitsugu Usui
Kimitsugu Usui
HTHideyuki Terao
Hideyuki Terao
TKTakeshi Kishida
Takeshi Kishida
Background/Aim: The number of available treatment options for urothelial carcinoma has increased recently. Upper tract urothelial carcinoma (UTUC) is relatively rare compared with bladder cancer. There are few reports on the efficacy of immune checkpoint inhibitors (ICIs) for metastatic UTUC, and ICIs may occasionally show less efficacy and cause severe side effects. Therefore, it is important to predict the treatment response and change the treatment strategy as appropriate. We investigated the prognostic factors for treatment response in patients with metastatic UTUC treated with pembrolizumab at our hospital. Patients and Methods: Patients who received pembrolizumab for UTUC between January 2018 and June 2023 were analyzed. Patients who presented with bladder cancer complications at initial diagnosis were excluded. The primary endpoints assessed were overall survival (OS) and progression-free survival (PFS). Statistical analyses were conducted using laboratory values obtained before and after pembrolizumab administration. The relationship between cancer and inflammation is important. Therefore, we analyzed this relationship using prognostic factors for urothelial carcinoma as previously reported. Specifically, pretreatment C-reactive protein (CRP) level, neutrophil-to-lymphocyte ratio (NLR), and NLR/albumin values were examined. Results: Forty-seven patients were analyzed. The median PFS was 66 days (24-107 days), and the median OS was 164 days (13-314 days). A CRP level <1 before the first cycle was a useful factor in the multivariate analysis for both OS and PFS [OS: p=0.004, hazard ratio (HR)=3.244, 95% confidence interval (CI)=1.464-7.104; PFS: p=0.003, HR=2.998, 95%CI=1.444-6.225]. Conclusion: CRP level is a prognostic factor for pembrolizumab treatment response in patients with UTUC.

30 July 2024 in IJU Case Reports
Verified
Journal Article
Open access
PDF file
HNHirotaka Nagasaka
Hirotaka Nagasaka
TSTakahisa Suzuki
Takahisa Suzuki
TKTakuya Kondo
Takuya Kondo
MKMitsuyuki Koizumi
Mitsuyuki Koizumi
HTHideyuki Terao
Hideyuki Terao
TKTakeshi Kishida
Takeshi Kishida
Background: Doege–Potter syndrome, characterized by solitary fibrous tumors and non‐islet cell tumor hypoglycemia, is rare. Here, we report a case of Doege–Potter syndrome in which retroperitoneal tumor resection was performed with continuous intraoperative blood glucose monitoring.Case presentation: A 37‐year‐old man presented with hypoglycemia‐related symptoms, and a 10 × 12 × 9 cm tumor was found in his right kidney. Following tumor resection, insulin secretory abnormalities improved, and intraoperative blood glucose monitoring showed no hypoglycemic events. High levels of insulin‐like growth factor‐II confirmed the diagnosis of an insulin‐like growth factor‐II‐producing tumor with non‐islet cell tumor hypoglycemia. Postoperative serum insulin‐like growth factor‐II levels normalized, with no recurrence observed over 3 years.Conclusions: This case highlights the rarity of primary retroperitoneal Doege–Potter syndrome, emphasizes the safety of intraoperative blood glucose levels during surgery, and suggests rapid recovery of insulin secretion postoperatively.

25 September 2023 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
HNHirotaka Nagasaka
Hirotaka Nagasaka
STShinichi Takebe
Shinichi Takebe
SYShotaro Yamamoto
Shotaro Yamamoto
TKTakuya Kondo
Takuya Kondo
HTHideyuki Terao
Hideyuki Terao
TKTakeshi Kishida
Takeshi Kishida
A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnosed with coronavirus disease (COVID-19). COVID-19 was suspected to worsen because of cancer and chemotherapy-induced immunosuppression. However, the benefits of continuing BEP therapy outweighed these risks. After obtaining fully informed consent, BEP therapy was continued from day 5, while sotrovimab (anti-COVID-19 drug) was administered. The second course of BEP was completed without worsening severe COVID-19 or bleomycin-induced lung injury. The patient completed four courses of BEP, with normalization of tumor markers, partial response on imaging, and improvement in lower body paralysis. In this case, we successfully treated a patient with testicular germ cell tumor with chemotherapy while having COVID-19 without treatment delay. During the COVID-19 pandemic, concomitant chemotherapy and COVID-19 treatment are warranted because delaying treatment will decrease the efficacy of highly curative diseases such as germ cell tumors.

22 December 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
GNGo Noguchi
Go Noguchi
MBMasaya Baba
Masaya Baba
SOShinji Ohtake
Shinji Ohtake
RJRyosuke Jikuya
Ryosuke Jikuya
TMTaku Mitome
Taku Mitome
HHHisashi Hasumi
Hisashi Hasumi
Although kidney cancer arises from a variety of nephron cells with diverse characteristics and develops intratumor heterogeneity, a model to elucidate these complexities is incompletely developed. In this study, we report a genetically engineered human induced pluripotent stem cell–derived kidney organoid (HKO) model, which may recapitulate an early stage of renal tumorigenesis. When we overexpressed the VCL-ALK fusion gene, a renal oncogene, in HKO, tubular cells proliferated, and this proliferation was sustained under long-term culture or hypoxic conditions. In addition, the proliferating tubular cells migrated into the renal parenchyma of host mice upon transplantation. The deconvolution analysis and IHC revealed that the proliferating tubular cells could be arrested at an immature tubular progenitor stage with increased expressions of LIM homeobox protein 1 and jagged canonical Notch ligand 1, critical regulators of nephrogenesis. Our HKO model advances our understanding of renal tumorigenesis in the context of the trajectory of nephron development. Implications: Dysregulated nephron developmental machinery leads to aberrant cell proliferation of immature renal tubules.

25 April 2023 in Research Square
Verified
Preprint
Open access
PDF file
HNHirotaka Nagasaka
Hirotaka Nagasaka
TSTakahisa Suzuki
Takahisa Suzuki
TKTakuya Kondo
Takuya Kondo
MKMitsuyuki Koizumi
Mitsuyuki Koizumi
HTHideyuki Terao
Hideyuki Terao
TKTakeshi Kishida
Takeshi Kishida
Background: Doege-Potter syndrome presents as solitary fibrous tumors and non-islet cell tumor hypoglycemia (NICTH). Here, we report a case of Doege-Potter syndrome in which retroperitoneal tumor resection was performed with continuous intraoperative blood glucose monitoring. Case Presentation: The patient was a 37-year-old healthy man with no relevant medical history. They were brought to the emergency room because of defecation difficulties and incontinence caused by hypoglycemia, and a tumor measuring 10 × 12 × 9 cm was found in the right kidney. High-molecular-weight insulin-like growth factor-II (IGF-II) was detected in the blood, indicating an IGF-II-producing tumor with NICTH. The patient underwent tumor resection, and the pathological results indicated a solitary fibrous tumor of retroperitoneal origin. Thus, retroperitoneal primary Doege-Potter syndrome was diagnosed. Continuous blood glucose monitoring was performed intraoperatively, and no hypoglycemic attacks occurred; insulin secretory abnormalities improved immediately after surgery. Previous studies suggest that IGF-II is metabolized in a few hours. Therefore, serum IGF-II levels were analyzed one week and one month postoperatively; the levels were within the normal range at both time points. Two years have passed since the surgery without recurrence. Conclusions: Doege-Potter syndrome of retroperitoneal primary origin is rare. Furthermore, continuous intraoperative blood glucose monitoring was performed during surgery; thus, we report blood glucose level trends for the first time. This case highlights that this type of surgery can be performed safely without special blood glucose adjustments and that insulin secretion resumes soon after surgery.